Schepart B S, Margolis M L
Department of Microbiology and Immunology, Medical College of Pennsylvania, Philadelphia 19129.
Am Rev Respir Dis. 1988 Dec;138(6):1434-8. doi: 10.1164/ajrccm/138.6.1434.
We assessed the ability of three monoclonal antibodies (MAbs) (5E8, 5C7, and 1F10) to detect tumor-associated antigens (TAAs) in the sera of patients seen in consultation by the Pulmonary Disease Section at the Philadelphia Veterans Administration Medical Center from September through November 1987. Eighteen of the 61 sera were obtained from patients with histologically established lung cancer. Using a semiquantitative enzyme-linked immunoassay (ELISA), TAAs were detected by the MAb panel in the sera of 12 lung cancer patients, yielding a sensitivity of 67% with a 95% confidence interval of 44 to 84%. The frequency of TAA detection varied among cell types and stages of disease. There were eight false positives and 35 true negatives, giving a specificity of 81% with a 95% confidence interval of 67 to 90%. Two of the false positives came from patients with nonpulmonary tumors known to cross-react with the MAbs (laryngeal and gastric carcinoma). The panel was able to distinguish patients with lung cancer from those without to a highly significant degree (chi 2 = 11.2 with 1 df, p less than 0.001). This study suggests that MAb-mediated detection of serum TAAs may be useful in diagnosing and characterizing lung cancers.
我们评估了三种单克隆抗体（MAb）（5E8、5C7和1F10）在检测1987年9月至11月间在费城退伍军人管理局医疗中心肺病科会诊的患者血清中肿瘤相关抗原（TAA）的能力。61份血清中的18份取自组织学确诊的肺癌患者。使用半定量酶联免疫吸附测定（ELISA），该单克隆抗体组在12例肺癌患者的血清中检测到了TAA，灵敏度为67%，95%置信区间为44%至84%。TAA检测频率在疾病的细胞类型和阶段中有所不同。有8例假阳性和35例真阴性，特异性为81%，95%置信区间为67%至90%。其中两例假阳性来自已知与单克隆抗体发生交叉反应的非肺部肿瘤患者（喉癌和胃癌）。该抗体组能够在很大程度上区分肺癌患者和非肺癌患者（卡方检验，自由度为1时卡方值 = 11.2，p < 0.001）。这项研究表明，单克隆抗体介导的血清TAA检测可能有助于肺癌的诊断和特征描述。
